litlas
Log inCreate account

Leisha A. Emens

Active 1992–2025

94
Papers
20,093
Citations
62
h-index
93
i10-index

Citations

Citations per year for Leisha A. Emens1993: 3 citations1994: 6 citations1996: 4 citations1997: 4 citations1998: 5 citations1999: 6 citations2000: 4 citations2001: 11 citations2002: 15 citations2003: 14 citations2004: 19 citations2005: 24 citations2006: 56 citations2007: 46 citations2008: 58 citations2009: 37 citations2010: 78 citations2011: 54 citations2012: 73 citations2013: 79 citations2014: 48 citations2015: 98 citations2016: 131 citations2017: 193 citations2018: 182 citations2019: 834 citations2020: 1,421 citations2021: 1,678 citations2022: 1,377 citations2023: 996 citations2024: 1,237 citations2025: 612 citations2026: 18 citations1995: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,724 citing papers, 24.6% of this breakdownChina: 1,993 citing papers, 18% of this breakdownItaly: 608 citing papers, 5.5% of this breakdownUnited Kingdom: 460 citing papers, 4.1% of this breakdownFrance: 435 citing papers, 3.9% of this breakdownGermany: 407 citing papers, 3.7% of this breakdownSpain: 329 citing papers, 3% of this breakdownAustralia: 306 citing papers, 2.8% of this breakdownJapan: 290 citing papers, 2.6% of this breakdownCanada: 289 citing papers, 2.6% of this breakdownBelgium: 242 citing papers, 2.2% of this breakdownSouth Korea: 231 citing papers, 2.1% of this breakdown
0%24.6%Other 24.9%

Institutions

Fields

  • Medicine57.5%
  • Biochemistry, Genetics and Molecular Biology20.5%
  • Immunology and Microbiology14.9%
  • Engineering3.1%
  • Neuroscience1.3%
  • Materials Science1%
  • Other1.7%

Topics

  • Cancer Immunotherapy and Biomarkers15.4%
  • Immunotherapy and Immune Responses8%
  • CAR-T cell therapy research4%
  • Immune Cell Function and Interaction3.9%
  • Immune cells in cancer3.7%
  • Cancer Cells and Metastasis2.8%
  • Other62.2%

Coauthors

All papers

Open in search
  1. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

    Authors: Peter Schmid, Sylvia Adams, Hope S. Rugo, Andreas Schneeweiss, Carlos H. Barrios, Hiroji Iwata, Véronique Dièras, Roberto Hegg, Seock‐Ah Im, Gail S. Wright, Volkmar Henschel, Luciana Molinero, Jane Yuet Ching Hui, Roel Funke, Amreen Husain, Eric P. Winer, Sherene Loi, Leisha A. Emens - New England Journal of Medicine 2018 cited by 4,369

  2. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Peter Schmid, Hope S. Rugo, Sylvia Adams, Andreas Schneeweiß, Carlos H. Barrios, Hiroji Iwata, Véronique Dièras, Volkmar Henschel, Luciana Molinero, Jane Yuet Ching Hui, Vidya Maiya, Amreen Husain, Eric P. Winer, Sherene Loi, Leisha A. Emens - The Lancet Oncology 2019 cited by 1,198

  3. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy

    Authors: Suzanne L. Topalian, Patrick M. Forde, Leisha A. Emens, Mark Yarchoan, Kellie N. Smith, Drew M. Pardoll - Cancer Cell 2023 cited by 277

  4. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

    Authors: Leisha A. Emens, Sylvia Adams, Carlos H. Barrios, Véronique Dièras, Hiroji Iwata, Sherene Loi, Hope S. Rugo, Andreas Schneeweiß, Eric P. Winer, Shilpen Patel, Volkmar Henschel, A. Swat, Manika Kaul, Luciana Molinero, Shilpen Patel, S.Y. Chui, P. Schmid - Annals of Oncology 2021 cited by 468

  5. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

    Authors: Leisha A. Emens, Cristina Cruz, Joseph P. Eder, Fadi Braiteh, Cathie T. Chung, Sara M. Tolaney, Irene Kuter, Rita Nanda, Philippe A. Cassier, Jean‐Pierre Delord, Michael S. Gordon, Ehab A. ElGabry, Ching-Wei Chang, Indrani Sarkar, William Grossman, Carol O’Hear, Marcella Fassò, Luciana Molinero, Peter Schmid - JAMA Oncology 2018 cited by 793

  6. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

    Authors: Leisha A. Emens, Francisco J. Esteva, Mark Beresford, Cristina Saura, Michelino De Laurentiis, Sung‐Bae Kim, Seock‐Ah Im, Yifan Wang, Roberto Salgado, Aruna Mani, Jigna Shah, Chiara Lambertini, Haiying Liu, Sanne Lysbet de Haas, Monika Patre, Sherene Loi - The Lancet Oncology 2020 cited by 375

  7. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy

    Authors: Mahrukh Huseni, Lifen Wang, Joanna E. Klementowicz, Kobe Yuen, Beatrice Breart, Christine Orr, Lifen Liu, Yijin Li, Vinita Gupta, Congfen Li, Deepali Rishipathak, Jing Peng, Yasin Şenbabaoğlu, Zora Modrušan, Shilpa Keerthivasan, Shravan Madireddi, Ying‐Jiun Chen, Eleanor J. Fraser, Ning Leng, Habib Hamidi, Hartmut Koeppen, James Ziai, Kenji Hashimoto, Marcella Fassò, Patrick Williams, David F. McDermott, Jonathan E. Rosenberg, Thomas Powles, Leisha A. Emens, Priti S. Hegde, Ira Mellman, Shannon J. Turley, Mark S. Wilson, Sanjeev Mariathasan, Luciana Molinero, Mark Merchant, Nathaniel R. West - Cell Reports Medicine 2023 cited by 183

  8. Breast Cancer Immunotherapy: Facts and Hopes

    Authors: Leisha A. Emens - Clinical Cancer Research 2017 cited by 929

  9. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

    Authors: Luc Dirix, István Takács, Guy Jérusalem, Petros Nikolinakos, Hendrik‐Tobias Arkenau, Andres Forero‐Torres, Ralph V. Boccia, Marc E. Lippman, Robert A. Somer, Martin Šmakal, Leisha A. Emens, Borys Hrinczenko, W. Jeff Edenfield, Jayne S. Gurtler, Anja von Heydebreck, H. Grote, Kevin M. Chin, Erika Hamilton - Breast Cancer Research and Treatment 2017 cited by 756

  10. The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

    Authors: Leisha A. Emens, Gary Middleton - Cancer Immunology Research 2015 cited by 821

  11. Targeting adenosine for cancer immunotherapy

    Authors: Robert D. Leone, Leisha A. Emens - Journal for ImmunoTherapy of Cancer 2018 cited by 543

  12. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

    Authors: Leisha A. Emens, Luciana Molinero, Sherene Loi, Hope S. Rugo, Andreas Schneeweiß, Véronique Dièras, Hiroji Iwata, Carlos H. Barrios, M. Nechaeva, Anh Nguyen‐Duc, Jane Yuet Ching Hui, Amreen Husain, Eric P. Winer, Sylvia Adams, Peter Schmid - JNCI Journal of the National Cancer Institute 2021 cited by 306

  13. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision

    Authors: Leisha A. Emens, Pedro Romero, Ana C. Anderson, Tullia C. Bruno, Christian M. Capitini, Deborah Collyar, James L. Gulley, Patrick Hwu, Avery D. Posey, Ann W. Silk, Jennifer A. Wargo - Journal for ImmunoTherapy of Cancer 2024 cited by 146

  14. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

    Authors: Leisha A. Emens, Paolo A. Ascierto, Phillip K. Darcy, Sandra Demaria, Alexander M.M. Eggermont, William L. Redmond, Barbara Seliger, Francesco M. Marincola - European Journal of Cancer 2017 cited by 562

  15. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

    Authors: Lawrence Fong, Andrew Hotson, John D. Powderly, Mario Sznol, Rebecca S. Heist, Toni K. Choueiri, Saby George, Brett Hughes, Matthew D. Hellmann, Dale R. Shepard, Brian I. Rini, Shivaani Kummar, Amy Weise, Matthew J. Riese, Ben Markman, Leisha A. Emens, Daruka Mahadevan, Jason J. Luke, Ginna G. Laport, Joshua Brody, Leonel F. Hernandez‐Aya, Philip Bonomi, Jonathan W. Goldman, Lyudmyla Berim, Daniel J. Renouf, Rachel Goodwin, Brian Munneke, Po Y. Ho, Jessica Hsieh, Ian McCaffery, Long Kwei, Stephen B. Willingham, Richard A. Miller - Cancer Discovery 2019 cited by 339

  16. Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

    Authors: Kyung Hae Jung, Patricia LoRusso, Howard A. Burris, Michael A. Gordon, Yung‐Jue Bang, Matthew D. Hellmann, Andrés Cervantes, María Ochoa de Olza, Aurélien Marabelle, F. Stephen Hodi, Myung‐Ju Ahn, Leisha A. Emens, Fabrice Barlési, Omid Hamid, Emiliano Calvo, David F. McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Lew Tsuhako, Kari M. Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S. Lindsey Davis - Clinical Cancer Research 2019 cited by 286

  17. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas

    Authors: Ashley Cimino‐Mathews, Elizabeth D. Thompson, Janis M. Taube, Xiaobu Ye, Lu Yao, Alan K. Meeker, Haiying Xu, Rajni Sharma, Kristen Lecksell, Toby C. Cornish, Nathan Cuka, Pedram Argani, Leisha A. Emens - Human Pathology 2015 cited by 338

  18. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer

    Authors: Hope S. Rugo, Sherene Loi, Sylvia Adams, Peter Schmid, Andreas Schneeweiß, Carlos H. Barrios, Hiroji Iwata, Véronique Dièras, Eric P. Winer, Mark Kockx, Dieter Peeters, Jane Yuet Ching Hui, Jennifer Lin, Anh Nguyen-Duc, Giuseppe Viale, Luciana Molinero, Leisha A. Emens - JNCI Journal of the National Cancer Institute 2021 cited by 140

  19. A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice

    Authors: Jeremy B. Foote, Marleen Kok, James M. Leatherman, Todd D. Armstrong, Bridget C. Marcinkowski, Laureen S. Ojalvo, David B. Kanne, Elizabeth M. Jaffee, Thomas W. Dubensky, Leisha A. Emens - Cancer Immunology Research 2017 cited by 149

  20. Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors

    Authors: Li Zhu, Jessica L. Narloch, Sayali Onkar, Marion Joy, Gloria Broadwater, Catherine Luedke, Allison Hall, Rim Kim, Katherine L. Pogue–Geile, Sarah Sammons, Naema Nayyar, Ugonma Chukwueke, Priscilla K. Brastianos, Carey K. Anders, Adam C. Soloff, Dario A.A. Vignali, George C. Tseng, Leisha A. Emens, Peter C. Lucas, Kimberly Blackwell, Steffi Oesterreich, Adrian V. Lee - Journal for ImmunoTherapy of Cancer 2019 cited by 124

  21. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

    Authors: Leisha A. Emens, Sylvia Adams, Ashley Cimino‐Mathews, Mary L. Disis, Margaret E. Gatti‐Mays, Alice Y. Ho, Kevin Kalinsky, Heather L. McArthur, Elizabeth A. Mittendorf, Rita Nanda, David B. Page, Hope S. Rugo, Krista M. Rubin, Hatem Soliman, Patricia A. Spears, Sara M. Tolaney, Jennifer K. Litton - Journal for ImmunoTherapy of Cancer 2021 cited by 81

  22. Immunotherapy Approaches for Breast Cancer Patients in 2023

    Authors: Leisha A. Emens, Sherene Loi - Cold Spring Harbor Perspectives in Medicine 2023 cited by 64

  23. Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies

    Authors: Evanthia T. Roussos Torres, Leisha A. Emens - Breast Cancer Research and Treatment 2021 cited by 44

  24. Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer

    Authors: Hanwen Wang, Chen Zhao, Cesar A. Santa‐Maria, Leisha A. Emens, Aleksander S. Popel - iScience 2022 cited by 39